Abstract:OBJECTIVE:To investigate the effect of small interfering RNA (siRNA) targeting human vascular endothelial growth factor (hVEGF) on A549 cell growth in nude mice and angiogenesis on chorioallantoic membrane (CAM) assay.METHODS:Three pairs of hVEGF siRNA-plasmid and non-silencing-plasmid were constructed, and transfected into A549 cells through lipofectamine 2000, respectively. The most effective pair of hVEGF siRNA-plasmid was selected by ELISA and real-time RT-PCR. A549 cells transfected with selected hVEGF siRNA- plasmid, A549 cells transfected with non-silencing-plasmid and A549 cells without transfection were inoculated into nude mice, respectively. Chick embryos were randomly divided into four groups and CAM was treated by different solutions for 48 h: culture media DMEM as negative control group,un-transfected A549 cell culture supernatants as positive control group, hVEGF siRNA A549 cell culture supernatants as hVEGF siRNA group and nonsilencing siRNA A549 cell culture supernatants as non-silencing siRNA group. The CAMs were harvested on d12 for microscopic assays.RESULT:Compared with control group, hVEGF siRNA-plasmid induced 48% reduction in hVEGF secretion by A549 cells accompanied by 70% reduction in hVEGF mRNA. Compared with non-silencing siRNA group, the mean tumor volume of murine xenograft was reduced by 58% in hVEGF siRNA group; time for xenografts growing to 50 mm(3)was delayed by 5.4 d. hVEGF contents in xenograft were reduced by 54%; but mean doubling time of tumors and the growth rate of tumors were not significantly reduced. In CAM assays, hVEGF content was zero in negative group, and in hVEGF siRNA group that was 40%-44% of non-silencing siRNA group or positive group; vessels branch points of CAM in hVEGF siRNA group or non-silencing siRNA group or positive group were increased by 45%-55% compared with negative group; total vessel length of CAM in hVEGF siRNA group was increased by 53% compared with negative group, while in non-silencing siRNA group or positive group that was increased by 97% or 99%. Compared with negative control group, the proliferation of microvessels was increased when cell culture supernatant with hVEGF was added in hVEGF siRNA group, significant proliferated vessels were observed in non-silencing siRNA group or positive group.CONCLUSION:A plasmid-mediated hVEGF siRNA has been constructed and verified, which can effectively downregulate the expression of hVEGF in human A549 cells, resulting in the inhibition of angiogenesis. hVEGF siRNA can delay initial growth of A549 tumor xenograft but not reduce the growth rate.

The Effect of Antibody Against Vascular Endothelial Growth Factor on Tumor Growth and Metastasis.

[The Effect of Antibody Against Vascular Endothelial Growth Factor (VEGF) on Tumor Metastasis].

Effect of Molecular Therapeutics on Liver Regeneration in a Murine Model.

The Effect of Anti-Vegf Antiserum on the Progression of Bladder Cancer in Mouse Model

Effect of transcatheter arterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor in cervical squamous cell carcinoma

A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Efficiently Inhibits Growth of VX2 Cells and VX2 Tumor Model of Hepatocellular Carcinoma in Rabbit by Transarterial Embolization-Mediated Sirna Delivery.

The Effect of Anti-Vegf Drugs (bevacizumab and Aflibercept) on the Survival of Patients with Metastatic Colorectal Cancer (Mcrc)

Inhibition of Growth and Metastases of Inoculated Human Prostate Cancer in Nude Mice by Antisense Vascular Endothelial rowth Factor

Hvegf Sirna Inhibits Initial Growth of A549 Tumor Cells in Nude Mice and Angiogenesis on CAM Assay

Differential Inhibition Of Fluid Accumulation And Tumor Growth In Two Mouse Ascites Tumors By An Antivascular Endothelial Growth Factor Permeability Factor Neutralizing Antibody

[Effects of Vascular Endothelial Growth Factor (VEGF) Antisense Oligodeoxynucleotide on Mrna and Expression of VEGF, Flt-1, and Kinase Insert Domain Containing Receptor and VEGF Excretion in Human Gallbladder Carcinoma Cells].

Anti-angiogenic Active Immunotherapy: a New Approach to Cancer Treatment

Clinical applications of VEGF-trap (aflibercept) in cancer treatment.

Inhibition of K562 Leukemia Angiogenesis and Growth by Expression of Antisense Vascular Endothelial Growth Factor (VEGF) Sequence

[Inhibition of K562 Cell Growth and Tumor Angiogenesis in Nude Mice by Antisense VEGF(121) Cdna Transfection].

Abstract 1356: Vascular Endothelial Growth Inhibitor - Potential Role in Targeted Therapy in Kidney Neoplasma Via Angiogenic Inhibition

Anti-tumor effects of vascular endothelial growth factor/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells

Inhibitory Effect of Antisense Vascular Endothelial Growth Factor 165 Eukaryotic Expression Vector on Proliferation of Hepatocellular Carcinoma Cells

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

Research Advance in Vascular Endothelial Growth Factor and Anti-Tumor

A Vegfr1 Antagonistic Peptide Inhibits Tumor Growth and Metastasis Through Vegfr1-Pi3k-Akt Signaling Pathway Inhibition